کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5524275 | 1546246 | 2017 | 7 صفحه PDF | دانلود رایگان |
- Y-90 ibritumomab tiuxetan was used as a part of a reduced-intensity conditioning regimen phase II multicenter trial
- Conditioning regimen with radioimmunotherapy is safe and well tolerated
- The addition of radioimmunotherapy results in a long-term progression-free survival of 44%
- No significant toxicities related to Y-90 ibritumomab tiuxetan have been reported
- Our 46-month median follow-up is the longest reported in a radioimmunotherapy allogeneic stem cell transplantation trial
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). Eligible patients had high-risk relapsed/refractory aggressive lymphoma. The conditioning regimen consisted of rituximab 250âmg (days â21 and â14), Y-90 ibritumomab IV (.4âm Ci/kg, day â14), fludarabine 30âmg/m2 i.v. (days â3 and â2) plus melphalan 70âmg/m2 i.v. (days â3 and â2) or 1 dose of melphalan and thiotepa 5âmg/kg (day â8). Donors were related. Eighteen patients were evaluable. At the time of transplantation, responses were complete remission (CR) (n = 7, 39%), partial remission (n = 6, 33%) or refractory disease (n = 4, 28%). Y-90-ibritumomab infusions were well tolerated, with no adverse reactions. Nonrelapse mortality at 1 year was 28%. Median follow-up was 46 (range, 39 to 55) months. Estimated 1-year progression-free survival (PFS) was 50%, and 4-year overall survival (OS) and PFS were both 44.4%. CR at the moment of AlloSCT had significant impact on PFS (71% versus 27%, Pâ=â.046) and OS (71% versus 27%, Pâ=â.047). Our results show that Y-90-ibritumomab-tiuxetan as a component of RIC for AlloSCT is feasible in patients with high-risk B cell lymphoma. Development of phase III clinical trials is needed to clarify the contribution of radioimmunotherapy to RIC AlloSCT.
Journal: Biology of Blood and Marrow Transplantation - Volume 23, Issue 1, January 2017, Pages 53-59